Physician profile
Warren E Weston
NPI 1821177262
$1,661.49
in general payments reported to CMS, 2019-2025
16 companies · $229 in 2025
The $229 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.43 · 2022: $480 · 2023: $840 · 2024: $98.15 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,166.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $497.80 | 2022-2024 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $228.53 | 2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $193.65 | 2022-2023 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $112.90 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $112.24 | 2022-2023 | Invega Trinza, Invega Sustenna, Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $100.33 | 2022-2023 | Trintellix |
| Neurocrine Biosciences, INC. | $85.58 | 2022-2023 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $77.27 | 2022-2023 | Uzedy |
| Indivior INC. | $65.30 | 2022 | |
| Alkermes, INC. | $55.47 | 2023 | Aristada, Lybalvi |
| Avanir Pharmaceuticals, INC. | $29.85 | 2022 | |
| Abbvie INC. | $26.38 | 2023 | Vraylar |
| Corium, LLC | $23.73 | 2022-2023 | Azstarys |
| Novo Nordisk INC | $19.31 | 2023 | Wegovy |
| Lundbeck LLC | $18.72 | 2023 | Rexulti |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $14.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warren Weston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.